drugset / Trial / NCT05650216
Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）
NaSingle-groupOpen-labelTreatment
Summary
NICE-RT study is a "safety run-in" and phase II trial evaluating the safety and efficacy of Camrelizumab combined with Nab-paclitaxel and Carboplatin and Radiotherapy in patients with resectable locally advanced esophageal squamous cell carcinoma.
Timeline
- Start
- 2022-12-25
- Primary completion
- 2023-12-25
- Completion
- 2024-12-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Carboplatin | Small molecule | 2 unknown | — |
| Subject | Nab-paclitaxel | Small molecule | 80 mg/m2 | — |